914 results on '"Rajkumar SV"'
Search Results
2. Effect of complete response on outcome following autologous stem cell transplantation for myeloma
3. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkinʼs lymphoma
4. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma
5. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma
6. Autologous stem cell transplantation for relapsed and primary refractory myeloma
7. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
8. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
9. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
10. S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
11. PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL--ANALYSIS FROM THE TOURMALINE-MM3 STUDY
12. Thalidomide for previously untreated indolent or smoldering multiple myeloma
13. Capitol 30-Gammapatie monoclonali di incerto significato (MGUS)
14. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group
15. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
16. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
17. Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients (Pts) with relapsed multiple myeloma (RMM) based on age: secondary analysis from the phase 3 study ASPIRE (NCT01080391)
18. Effect of carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma by line of therapy: interim results from the phase 3 ASPIRE study
19. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib:A multicenter international myeloma working group study
20. Ineffectiveness of pulmonary irradiation in the treatment of leukemic blast crisis
21. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
22. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
23. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
24. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib
25. Management of treatment-emergent peripheral neuropathy in multiple myeloma
26. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
27. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
28. International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
29. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
30. International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
31. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
32. International Myeloma Workshop Consensus Panel 3. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
33. International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
34. International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
35. КОНСЕНСУС МЕЖДУНАРОДНОЙ РАБОЧЕЙ ГРУППЫ ПО МИЕЛОМЕ И РЕКОМЕНДАЦИИ ПО СОВРЕМЕННОЙ РОЛИ МЕТОДИК ВИЗУАЛИЗАЦИИ В ДИАГНОСТИКЕ И МОНИТОРИНГЕ МНОЖЕСТВЕННОЙ МИЕЛОМЫ
36. Prevention of thalidomide and lenalidomide associated trombosis in myeloma
37. SPOTLIGHT REVIEW
38. Treatment of plasma cell dyscrasias with lenalidomide
39. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma
40. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
41. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma
42. Screening mammography in women aged 40-49 years
43. A366 Relevance of Conventional Prognostic Factors in Multiple Myeloma (MM) in the Era of Novel Therapies
44. A282 Dexamethasone and Adrenal Suppression in Myeloma
45. A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM
46. A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma
47. A222 Survival and Years of Life Lost in Different Age Categories of Patients with Multiple Myeloma
48. A360 Skeletal Microstructural Changes in MGUS
49. Laboratory persistence and clinical progression of small monoclonal abnormalities.
50. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.